Related Experiment Video
Updated: Jan 17, 2026

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents
Published on: September 1, 2011
Brexpiprazole: Pioneering medication for managing agitation in Alzheimer's disease
Ayesha Shaukat1, Rumaisa Riaz1, Nawal Khaliq1
1Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Abstract:
Alzheimer's disease poses intricate challenges, affecting cognition and behavior, notably marked by agitation. The FDA's approval of brexpiprazole, an atypical antipsychotic, stands as a milestone, representing the first treatment for Alzheimer's-related agitation. brexpiprazole's modulation of serotonin-dopamine activity has proven effective in clinical trials, reducing agitation as measured by CMAI scores. Gradual dosage escalation is recommended, with potential side effects including nasopharyngitis, urinary tract infections, dizziness, somnolence, headache, and insomnia. Also useful for schizophrenia and treatment-resistant depression, providing ongoing treatment and potential well-being enhancement by managing agitation and other symptoms.
Related Concept Videos
Alzheimer's Disease: Treatment
Antidepressant Drugs: MAOIs and Other Agents
Psychosis: Goals of Pharmacotherapy
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Psychosis and Antipsychotic Drugs: Overview
Anxiolytic Drugs: Benzodiazepines and Buspirone

